Author:
McShane Lisa M.,Cavenagh Margaret M.,Lively Tracy G.,Eberhard David A.,Bigbee William L.,Williams P. Mickey,Mesirov Jill P.,Polley Mei-Yin C.,Kim Kelly Y.,Tricoli James V.,Taylor Jeremy M. G.,Shuman Deborah J.,Simon Richard M.,Doroshow James H.,Conley Barbara A.
Publisher
Springer Science and Business Media LLC
Reference19 articles.
1. Institute of Medicine. Evolution of
Translational Omics: Lessons Learned and the Path Forward (eds
Micheel, C. M., Nass, S. & Omenn, G. S. ) (The National Academies Press,
2012)A report produced by a committee formed in response
to an NCI request for recommendations to strengthen omics-based test development
and evaluation; this identifies best practices to enhance the development,
evaluation and translation of omics-based tests while reinforcing steps to
ensure that these tests are appropriately assessed for scientific validity
before they are used to guide patient treatment in clinical
trials.
2. McShane, L. M. et al. Criteria for the use of omics-based
predictors in clinical trials: explanation & elaboration. BMC Med.11, 220 (2013)This paper is
an annotated companion to the short version of the guidelines presented here,
elucidating the rationale underlying the development of the criteria in greater
detail.
3. Moore, H. M. et al. Biospecimen Reporting for Improved Study
Quality (BRISQ). Cancer Cytopath.119, 92–101 (2011)
4. Dobbin, K. K. et al. Interlaboratory comparability study of cancer
gene expression analysis using oligonucleotide microarrays. Clin. Cancer Res.11, 565–572 (2005)
5. Shi, L. et al. The MicroArray Quality Control (MAQC) project shows
inter- and intraplatform reproducibility of gene expression measurements.Nature Biotechnol.24, 1151–1161 (2006)
Cited by
187 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献